Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06192849 | To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | recruiting | Phase 2 | 20 | Juan LI, MDOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06188650 | The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study | recruiting | N/A | 30 | Ningbo Medical Center Lihuili Hospital |
| 1 |
| Jan 3, 2024 |
| clinicaltrials |
| NCT05689619 | SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)(SILMET) | recruiting | N/A | 70 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06142058 | RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC | recruiting | — | 44 | Xueqin YangOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06116019 | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)(ART-02) | recruiting | — | 649 | Charite University, Berlin, GermanyOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05997719 | Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC | recruiting | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05550961 | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch | recruiting | — | 1,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05241028 | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05724004 | Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)(A-SAB) | recruiting | N/A | 70 | Karolinska University HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06056115 | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | recruiting | N/A | 20 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | recruiting | Phase 3 | 570 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05732974 | A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse(MIRACLE) | recruiting | — | 60 | University Hospital, ToulouseOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043973 | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance | recruiting | Phase 3 | 98 | Qianfoshan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04728724 | Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03742687 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | recruiting | N/A | 151 | Danish Lung Cancer GroupOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05841472 | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | CrystalGenomics, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06001151 | Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative(ACHELOUS) | recruiting | Phase 2 | 49 | Qian ChuOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03786003 | ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) | recruiting | N/A | 1,086 | Fudan UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05837052 | A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | recruiting | Phase 2 | 49 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | recruiting | Phase 2 | 41 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05934032 | National Network Genomic Medicine Lung Cancer, Germany(nNGM) | recruiting | — | 30,000 | Prof. Dr. Juergen WolfOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05913089 | A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | recruiting | Phase 2 | 58 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05778708 | Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients | recruiting | N/A | 318 | The University of Hong KongOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | recruiting | Phase 1 / Phase 2 | 140 | Shanghai Chest HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01994057 | A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment | recruiting | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05800340 | Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05778253 | The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC | recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05286957 | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC(Seagull) | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05736029 | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics(PROPHETIC) | recruiting | — | 350 | OncoHost Ltd.INDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05537922 | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | recruiting | — | 2,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 4 | Jan 6, 2023 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT04720339 | Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. | recruiting | N/A | 250 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05339568 | Patient's Whole Process Follow-up Management(HOPE-1)(HOPE-1) | recruiting | — | 1,268 | Qianfoshan HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | recruiting | Phase 2 | 96 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04926584 | Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option(KOMPASSneo) | recruiting | — | 50 | Klinikum EsslingenOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05498064 | A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | recruiting | — | 490 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2024source: clinicaltrials